影像引导的心脏保护治疗在社区老年B期心力衰竭人群中的应用
研究在618例有HF风险的社区无症状患者(年龄71±5岁)中,随机比较先进超声心动图(心肌形变和详细舒张功能)引导的医疗与常规医疗,随访1年。先进超声心动图识别出219例SBHF并建议治疗,但两组HF发生率无差异(p=0.47),可能因仅43%启动治疗、仅9%达到目标剂量。在需要治疗且依从治疗者中,影像引导医疗使主要结局风险降低77%(p=0.04)。
要点
- 先进超声心动图通过应变和舒张功能评估可识别社区无症状B期心力衰竭患者。
- 影像引导治疗建议后仅43%启动治疗、仅9%达到目标剂量,总体HF发生率两组无差异(p=0.47)。
- 在需要治疗且依从治疗者中,影像引导医疗使主要复合终点风险降低77%(p=0.04)。
核心结论
- 基于应变和舒张功能评估检出B期心力衰竭与更高的HF发生率和死亡相关;血管紧张素转换酶抑制和β肾上腺素受体阻断的药物治疗效果受限于其 uptake,应考虑替代策略。
研究设计与样本
- 前瞻性随机开放盲终点(PROBE)设计,2013年9月13日至2015年11月6日纳入618例有HF风险的社区无症状患者(年龄71±5岁),随机分为先进超声心动图(心肌形变和详细舒张功能)引导医疗组与常规医疗组,随访1年。
诊断标准与关键数值
- 先进超声心动图(心肌形变和详细舒张功能)识别出219例B期心力衰竭并建议治疗。
- 在需要治疗且依从治疗者中,影像引导医疗的主要结局风险降低77%(p=0.04)。
- 总体两组HF发生率无差异(p=0.47),可能因仅43%启动治疗、仅9%达到目标剂量。
临床应用与阅片要点
- 先进超声心动图可用于社区无症状HF风险人群的B期心力衰竭筛查。
- 影像检出B期心力衰竭后建议患者及其初级医生启动血管紧张素转换酶抑制和β肾上腺素受体阻断治疗。
局限性
- 仅43%启动治疗,仅9%达到目标剂量,限制了药物治疗效果的评估。
- 影像引导医疗的获益仅在需要治疗且依从治疗者中观察到(p=0.04)。
- 作者结论提出应考虑替代策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of the study was to evaluate the benefit of care guided by the detection of stage B heart failure (SBHF) using advanced echocardiography for the reduction of new HF in the community.
BACKGROUND: The detection of nonischemic SBHF has been facilitated by advanced echocardiographic imaging modalities. However, improved outcomes have not been proven as they are predicated on benefit of treatment.
METHODS: Between September 13, 2013 and November 6, 2015, 618 asymptomatic community-based patients with HF risks (age 71 ± 5 years) were randomized to care guided by advanced echocardiography (myocardial deformation and detailed diastolic function) versus usual care. Evidence of SBHF led to advice to the patients and their primary physicians to initiate treatment with angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade. The trial followed the PROBE (Prospective Randomized Open Blinded Endpoint) design. Participants were followed for 1 year for the primary composite endpoint of death from cardiovascular causes and new HF.
RESULTS: Advanced echocardiography identified 219 as having SBHF and treatment was advised. Over a mean follow-up of 13 ± 6 months, 67 reached the primary endpoint. The incidence rate of HF was no different between the 2 arms (p = 0.47), likely because only 43% initiated therapy, and only 9% achieved target dose. Among subjects needing therapy on the basis of imaging and adherence to therapy, imaging-guided care showed a 77% lower hazard for the primary outcome (p = 0.04).
CONCLUSIONS: The detection of SBHF from strain and diastolic function evaluation was associated with a higher incidence of incidence HF and death. The efficacy of pharmacological intervention with angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade is limited by its uptake, and alternative strategies should be considered. (Tasmanian Study of Echocardiographic Detection of Left Ventricular Dysfunction [TAS-ELF]; ACTRN12614000080628).
引用
- Yang H, Negishi K, Wang Y, et al. Imaging-Guided Cardioprotective Treatment in a Community Elderly Population of Stage B Heart Failure. JACC Cardiovasc Imaging. 2017. PMID: 28279368. doi:10.1016/j.jcmg.2016.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。